<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PRAMIPEXOLE DIHYDROCHLORIDE</span><br/>(pra-mi-pex'ole)<br/><span class="topboxtradename">Mirapex<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">anticholinergic (parasympathomimetic)</span>; <span class="classification">antiparkinsonism agent</span><br/><b>Prototype: </b>Dopamine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.125 mg, 0.25 mg, 1 mg, 1.5 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Nonergot dopamine receptor agonist structurally similar to ropinirole for treatment of Parkinson's disease. Exhibits high
         affinity for the D<sub>2</sub> subfamily of dopamine receptors in the brain and higher binding affinity to D<sub>3</sub> than to D<sub>2</sub> or D<sub>4</sub> dopamine receptor subtypes. Precise mechanism of action and treatment for Parkinson's disease is not known.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Increases level of dopamine in the brain, since it binds to the dopamine receptors. Effectiveness is indicated by improved
         control of neuromuscular functioning.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of idiopathic Parkinson's disease.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to pramipexole or ropinirole; lactation; pregnancy (category C).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal and liver function impairment; concomitant use of CNS depressants. Safety and efficacy in children are not established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Parkinson's Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 0.125 mg t.i.d. times 1 wk, then 0.25 mg t.i.d. times 1 wk, continue to increase by 0.25 mg/dose t.i.d. qwk to
               a target dose of 1.5 mg t.i.d.<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> 3560 mL/min: same titration schedule dosed b.i.d. (max: 1.5 mg b.i.d.); 1535 mL/min: same titration schedule
               dosed q.d. (max: 1.5 mg q.d.)<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Titrate dose increments gradually with at least 57 d between increases.</li>
<li>Reduce doses for creatinine clearance &gt;60 mL/min.</li>
<li>Give with food if nausea develops.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> <span class="speceff-common">Asthenia,</span> general edema, malaise, fever, decreased weight. <span class="typehead">CNS:</span> <span class="speceff-common">Dizziness, somnolence, sudden sleep attacks, insomnia, hallucinations, dyskinesia, extrapyramidal syndrome,</span> headache, confusion, amnesia, hypesthesia, dystonia, akathisia, myoclonus, peripheral edema. <span class="typehead">CV:</span> <span class="speceff-common">Postural hypotension,</span> chest pain. <span class="typehead">GI:</span> <span class="speceff-common">Nausea, constipation,</span> anorexia, dysphagia, dry mouth. <span class="typehead">Respiratory:</span> Dyspnea, rhinitis. <span class="typehead">Urogenital:</span> Decreased libido, impotence, urinary frequency or incontinence. <span class="typehead">Special Senses:</span> Vision abnormalities. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Cimetidine</b> decreases clearance; <span class="classification">butyrophenones</span>, <b>metoclopramide</b>, <span class="classification">phenothiazines</span> may antagonize effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract &gt;90% bioavailability. <span class="typehead">Peak:</span> 2 h. <span class="typehead">Distribution:</span> 15% protein bound. <span class="typehead">Metabolism:</span> Minimally metabolized in the liver. <span class="typehead">Elimination:</span> Primarily excreted in urine. <span class="typehead">Half-Life:</span> 812 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of orthostatic hypotension, especially when the dosage is increased.</li>
<li>Monitor cardiac status, especially in those with significant orthostatic hypotension.</li>
<li>Lab tests: Monitor BUN and creatinine periodically; monitor CPK with complaints of muscle pain.</li>
<li>Monitor for and report signs of tardive dyskinesia (see Appendix F).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Hallucinations are an adverse effect of this drug and occur more often in older adults.</li>
<li>Make position changes slowly especially from a lying or sitting to standing.</li>
<li>Use caution with potentially dangerous activities until response to drug is known; drowsiness is a common adverse effect.</li>
<li>Avoid alcohol and use extra caution if taking other prescribed CNS depressants; both may exaggerate drowsiness, dizziness,
            and orthostatic hypotension.
         </li>
<li>Do not abruptly stop taking this drug. It should be discontinued over a period of 1 wk.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>